5,868 Shares in Quest Diagnostics Incorporated $DGX Purchased by Callan Family Office LLC

Key Points

• Callan Family Office acquired 5,868 Quest Diagnostics shares worth approximately $1.24 million. Institutional investors collectively own 88.06% of the company.
• Quest Diagnostics exceeded quarterly expectations, reporting $3.12 in EPS versus the $2.82 consensus and $3.04 billion in revenue, up 10.2% year over year. Analysts maintain a “Moderate Buy” consensus with an average price target of $235.31.
• The company declared a quarterly dividend of $0.86 per share, or $3.44 annualized, representing a 1.4% yield and a 36.52% payout ratio.

Callan Family Office LLC acquired a new stake in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 5,868 shares of the medical research company's stock, valued at approximately $1,244,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Quest Diagnostics by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 14,392,082 shares of the medical research company's stock worth $2,497,458,000 after buying an additional 140,450 shares in the last quarter. BlackRock Inc. bought a new position in Quest Diagnostics in the 2nd quarter valued at about $1,965,923,000. State Street Corp raised its position in shares of Quest Diagnostics by 3.0% in the 4th quarter. State Street Corp now owns 5,382,547 shares of the medical research company's stock valued at $934,033,000 after buying an additional 158,617 shares in the last quarter. Boston Partners raised its position in shares of Quest Diagnostics by 32.8% in the 3rd quarter. Boston Partners now owns 4,036,881 shares of the medical research company's stock valued at $767,978,000 after buying an additional 997,033 shares in the last quarter. Finally, Morgan Stanley lifted its holdings in shares of Quest Diagnostics by 17.8% during the 4th quarter. Morgan Stanley now owns 2,693,568 shares of the medical research company's stock worth $467,415,000 after acquiring an additional 406,658 shares during the period. Institutional investors and hedge funds own 88.06% of the company's stock.

Insider Activity

In other news, SVP Mark E. Delaney sold 1,600 shares of the firm's stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total transaction of $376,288.00. Following the completion of the transaction, the senior vice president owned 10,335 shares of the company's stock, valued at approximately $2,430,585.30. This trade represents a 13.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the transaction, the chief executive officer owned 132,423 shares in the company, valued at approximately $25,708,601.22. This trade represents a 7.02% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 19,747 shares of company stock valued at $3,947,088. Insiders own 0.88% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on DGX. Mizuho increased their price target on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Argus set a $260.00 price objective on shares of Quest Diagnostics in a research report on Wednesday, July 29th. Truist Financial upped their target price on Quest Diagnostics from $225.00 to $250.00 and gave the stock a "hold" rating in a research note on Friday, July 24th. UBS Group raised their target price on Quest Diagnostics from $220.00 to $232.00 and gave the company a "neutral" rating in a report on Friday, July 24th. Finally, Robert W. Baird lifted their price target on Quest Diagnostics from $236.00 to $255.00 and gave the company a "neutral" rating in a research note on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $235.31.

Quest Diagnostics Stock Performance

Shares of DGX stock opened at $244.34 on Monday. The firm has a market capitalization of $26.97 billion, a price-to-earnings ratio of 25.94, a PEG ratio of 2.25 and a beta of 0.56. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. The business's 50-day moving average price is $219.35 and its 200-day moving average price is $205.29. Quest Diagnostics Incorporated has a 12 month low of $171.18 and a 12 month high of $245.68.

Quest Diagnostics (NYSE:DGX - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.82 by $0.30. The company had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The firm's revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Equities research analysts forecast that Quest Diagnostics Incorporated will post 11.15 EPS for the current year.

Quest Diagnostics Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Shareholders of record on Tuesday, October 6th will be given a $0.86 dividend. This represents a $3.44 annualized dividend and a yield of 1.4%. The ex-dividend date is Tuesday, October 6th. Quest Diagnostics's dividend payout ratio is 36.52%.

About Quest Diagnostics

Quest Diagnostics NYSE: DGX is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source